Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Pediatrics Reports
Published in: Current Pediatrics Reports 3/2022

Open Access 01-09-2022 | International Health (EG Lago and N Gupta, Section Editors)

Building Programs to Eradicate Toxoplasmosis Part I: Introduction and Overview

Authors: Mariangela Soberón Felín, Kanix Wang, Aliya Moreira, Andrew Grose, Karen Leahy, Ying Zhou, Fatima Alibana Clouser, Maryam Siddiqui, Nicole Leong, Perpetua Goodall, Morgan Michalowski, Mahmoud Ismail, Monica Christmas, Stephen Schrantz, Zuleima Caballero, Ximena Norero, Dora Estripeaut, David Ellis, Catalina Raggi, Catherine Castro, Davina Moossazadeh, Margarita Ramirez, Abhinav Pandey, Kevin Ashi, Samantha Dovgin, Ashtyn Dixon, Xuan Li, Ian Begeman, Sharon Heichman, Joseph Lykins, Delba Villalobos-Cerrud, Lorena Fabrega, José Luis Sanchez Montalvo, Connie Mendivil, Mario R. Quijada, Silvia Fernández-Pirla, Valli de La Guardia, Digna Wong, Mayrene Ladrón de Guevara, Carlos Flores, Jovanna Borace, Anabel García, Natividad Caballero, Claudia Rengifo-Herrera, Maria Theresa Moreno de Saez, Michael Politis, Kristen Wroblewski, Theodore Karrison, Stephanie Ross, Mimansa Dogra, Vishan Dhamsania, Nicholas Graves, Marci Kirchberg, Kopal Mathur, Ashley Aue, Carlos M. Restrepo, Alejandro Llanes, German Guzman, Arturo Rebellon, Kenneth Boyer, Peter Heydemann, A. Gwendolyn Noble, Charles Swisher, Peter Rabiah, Shawn Withers, Teri Hull, Chunlei Su, Michael Blair, Paul Latkany, Ernest Mui, Daniel Vitor Vasconcelos-Santos, Alcibiades Villareal, Ambar Perez, Carlos Andrés Naranjo Galvis, Mónica Vargas Montes, Nestor Ivan Cardona Perez, Morgan Ramirez, Cy Chittenden, Edward Wang, Laura Lorena Garcia-López, Juliana Muñoz-Ortiz, Nicolás Rivera-Valdivia, María Cristina Bohorquez-Granados, Gabriela Castaño de-la-Torre, Guillermo Padrieu, Juan David Valencia Hernandez, Daniel Celis-Giraldo, Juan Alejandro Acosta Dávila, Elizabeth Torres, Manuela Mejia Oquendo, José Y. Arteaga-Rivera, Dan L. Nicolae, Andrey Rzhetsky, Nancy Roizen, Eileen Stillwaggon, Larry Sawers, Francois Peyron, Martine Wallon, Emanuelle Chapey, Pauline Levigne, Carmen Charter, Migdalia De Frias, Jose Montoya, Cindy Press, Raymund Ramirez, Despina Contopoulos-Ioannidis, Yvonne Maldonado, Oliver Liesenfeld, Carlos Gomez, Kelsey Wheeler, Ellen Holfels, David Frim, David McLone, Richard Penn, William Cohen, Samantha Zehar, James McAuley, Denis Limonne, Sandrine Houze, Sylvie Abraham, Raphael Piarroux, Vera Tesic, Kathleen Beavis, Ana Abeleda, Mari Sautter, Bouchra El Mansouri, Adlaoui El Bachir, Fatima Amarir, Kamal El Bissati, Alejandra de-la-Torre, Gabrielle Britton, Jorge Motta, Eduardo Ortega-Barria, Isabel Luz Romero, Paul Meier, Michael Grigg, Jorge Gómez-Marín, Jagannatha Rao Kosagisharaf, Xavier Sáez Llorens, Osvaldo Reyes, Rima McLeod

Published in: Current Pediatrics Reports | Issue 3/2022

Login to get access

Abstract

Purpose of Review

Review building of programs to eliminate Toxoplasma infections.

Recent Findings

Morbidity and mortality from toxoplasmosis led to programs in USA, Panama, and Colombia to facilitate understanding, treatment, prevention, and regional resources, incorporating student work.

Summary

Studies foundational for building recent, regional approaches/programs are reviewed. Introduction provides an overview/review of programs in Panamá, the United States, and other countries. High prevalence/risk of exposure led to laws mandating testing in gestation, reporting, and development of broad-based teaching materials about Toxoplasma. These were tested for efficacy as learning tools for high-school students, pregnant women, medical students, physicians, scientists, public health officials and general public. Digitized, free, smart phone application effectively taught pregnant women about toxoplasmosis prevention. Perinatal infection care programs, identifying true regional risk factors, and point-of-care gestational screening facilitate prevention and care. When implemented fully across all demographics, such programs present opportunities to save lives, sight, and cognition with considerable spillover benefits for individuals and societies.
Appendix
Available only for authorised users
Literature
1.
•• Mcleod R, Mack DG, Boyer K, Mets M, Roizen N, Swisher C, Patel D, Beckmann E, Vitullo D, Johnson D, et al. Phenotypes and functions of lymphocytes in congenital toxoplasmosis. J Lab Clin Med. 1990;116(5):623–35 Parasite specific unresponsiveness in tests of cell mediated immunity in US children with congenital toxoplasmosis.PubMed
2.
McGee T, Wolters C, Stein L, Kraus N, Johnson D, Boyer K, Mets M, Roizen N, Beckman J, Meier P, Swisher C, Holfels E, Withers S, McLeod R. Absence of sensorineural hearing loss in treated infants and children with congenital toxoplasmosis. Otolaryngol Head Neck Surg. 1992;106(1):75–80 Identifies that in the US in treated children sensorineural hearing loss is very rare.PubMedCrossRef
3.
•• Mcleod R, Mack D, Foss R, Boyer K, Withers S, Levin S, Hubbell J. Levels of pyrimethamine in sera and cerebrospinal and ventricular fluids from infants treated for congenital toxoplasmosis. Toxoplasmosis Study Group. Antimicrob Agents Chemother. 1992;36(5):1040–8 Presents pyrimethamine pharmacokinetics in infants and children and that treatment can be used safely in the first year of life. Outcomes for some children were markedly better than for comparable children in prior literature.PubMedPubMedCentralCrossRef
4.
•• McAuley J, Boyer KM, Patel D, Mets M, Swisher C, Roizen N, Wolters C, Stein L, Stein M, Schey W, Remington J, Meier P, Johnson D, Heydemann P, Holfels E, Withers S, Mack D, Brown C, Patton D, McLeod R. Early and longitudinal evaluations of treated infants and children and untreated historical patients with congenital toxoplasmosis: the Chicago Collaborative Treatment Trial. Clin Infect Dis. 1994;18(1):38–72 Systematic diagnosis and follow up of treated and untreated children and the beginning of a randomized treatment study.PubMedCrossRef
5.
•• Swisher CN, Boyer K, McLeod R. Congenital toxoplasmosis. In JB Bodensteiner, Ed. Semin Pediatr Neurol. 1994;1:4–25 Describes neurologic findings of congenital toxoplasmosis in the United States.PubMed
6.
•• Roizen N, Swisher CN, Stein MA, Hopkins J, Boyer KM, Holfels E, Mets MB, Stein L, Patel D, Meier P, Withers S, Remington J, Mack D, Heydemann P, Patton D, McLeod R. Neurologic and developmental outcome in treated congenital toxoplasmosis. Pediatrics. 1995;95(1):11–20 Demonstrates better neurologic outcomes and the importance of recognizing that what may be interpreted as developmental delays may really be related to visual impairment. This emphasizes the importance of compensatory educational strategies.PubMed
7.
•• Patel DV, Holfels EM, Vogel NP, Boyer KM, Mets MB, Swisher CN, Roizen NJ, Stein LK, Stein MA, Hopkins J, Withers SE, Mack DG, Luciano RA, Meier P, Remington JS, McLeod RL. Resolution of intracranial calcifications in infants with treated congenital toxoplasmosis. Radiology. 1996;199(2):433–40 Identifies that intracranial calcifications in infants with congenital toxoplasmosis resolve or diminish in size with treatment.PubMedCrossRef
8.
•• Vogel N, Kirisits M, Michael E, Bach H, Hostetter M, Boyer K, Simpson R, Holfels E, Hopkins J, Mack D, Mets MB, Swisher CN, Patel D, Roizen N, Stein L, Stein M, Withers S, Mui E, Egwuagu C, et al. Congenital toxoplasmosis transmitted from an immunologically competent mother infected before conception. Clin Infect Dis. 1996;23:1055–60 Identifies that occasionally preconception infection can be transmitted to a fetus even when the pregnant women did not have known immunocompromise.PubMedCrossRef
9.
•• Mets MB, Holfels E, Boyer KM, Swisher CN, Roizen N, Stein L, Stein M, Hopkins J, Withers S, Mack D, Luciano R, Patel D, Remington JS, Meier P, McLeod R. Eye manifestations of congenital toxoplasmosis. Am J Ophthalmol. 1996;122:309–24 Characterizes ocular toxoplasmosis with congenital infection, that it can be treated effectively without loss of vision in recurrences, and the timing of recurrences especially at school age entry, adolescence, and with significant stress.PubMedCrossRef
10.
•• Roberts F, McLeod R. Pathogenesis of toxoplasmic retinochoroiditis. Parasitol Today. 1999;15:51–7 Identifies pathogenic mechanisms in toxoplasmic retinochoroiditis.PubMedCrossRef
11.
•• Mack DG, Johnson JJ, Roberts F, Roberts CW, Estes RG, David C, Grumet FC, Mcleod R. HLA-class II genes modify outcome of Toxoplasma gondii infection. Int J Parasitol. 1999;29:1351–8 Identifies HLA Class II susceptibility alleles.PubMedCrossRef
12.
Lyons RE, Lyons K, McLeod R, Roberts CW. Construction and validation of a polycompetitor construct (SWITCH) for use in competitive RT-PCR to assess tachyzoite-bradyzoite interconversion in Toxoplasma gondii. Parasitology. 2001;123:433–9 Quantitating parasite tachyzoite and bradyzoite burden by PCR.PubMedCrossRef
13.
Brezin AP, Thulliez P, Couvreur J, Nobre R, McLeod R, Mets MB. Ophthalmic outcomes after prenatal and postnatal treatment of congenital toxoplasmosis. Am J Ophthalmol. 2003;135:779–84 Contrasts retinal disease in French and US children.PubMedCrossRef
14.
•• Boyer KM, Holfels E, Roizen N, Swisher C, Mack D, Remington J, Withers S, Meier P, McLeod R. Risk factors for Toxoplasma gondii infection in mothers of infants with congenital toxoplasmosis: Implications for prenatal management and screening. Am J Obstet Gynecol. 2005;192:564–71 Identifies risk factors and lack of recognition of these factors by mothers with infants with congenital toxoplasmosis in the US.PubMedCrossRef
15.
•• McLeod R, Khan AR, Noble GA, Latkany P, Jalbrzikowski J, Boyer K. Severe sulfadiazine hypersensitivity in a child with reactivated congenital toxoplasmic chorioretinitis. Pediatr Infect Dis J. 2006;25:270–2 Emphasizes that severe hypersensitivity with sulfonamides can occur with treatment of ocular toxoplasmosis, in this case DRESS syndrome which can be lethal.PubMedCrossRef
16.
•• Roizen N, Kasza K, Karrison T, Mets M, Noble AG, Boyer K, Swisher C, Meier P, Remington J, Jalbrzikowski J, McLeod R, Kipp M, Rabiah P, Chamot D, Estes R, Cezar S, Mack D, Pfiffner L, Stein M, et al. Impact of visual impairment on measures of cognitive function for children with congenital toxoplasmosis: implications for compensatory intervention strategies. Pediatrics. 2006;118:e379–90 Emphasizes the effect of visual impairment on the measurement of cognition in congenital toxoplasmosis and the importance of compensatory strategies.PubMedCrossRef
17.
•• McLeod R, Boyer K, Karrison T, Kasza K, Swisher C, Roizen N, Jalbrzikowski J, Remington J, Heydemann P, Noble AG, Mets M, Holfels E, Withers S, Latkany P, Meier P. Outcome of treatment for congenital toxoplasmosis, 1981-2004: The National Collaborative Chicago-Based, Congenital Toxoplasmosis Study. Clin Infect Dis. 2006;42:1383–94 Presents data for the National Collaborative Toxoplasmosis study over 23 years considering pre-specified endpoints, comparing the results with two doses of pyrimethamine following randomization, calculating Kaplan Meier analyses of endpoints, and documenting substantially better outcomes than in earlier literature.PubMedCrossRef
18.
• Arun V, Noble AG, Latkany P, Troia RN, Jalbrzikowski J, Kasza K, Karrison T, Cezar S, Sautter M, Greenwald MJ, Mieler W, Mets MB, Alam A, Boyer K, Swisher CN, Roizen N, Rabiah P, Del Monte MA, McLeod R. Cataracts in congenital toxoplasmosis. J AAPOS. 2007;11:551–4 Identifies types of cataracts and their treatment in congenital toxoplasmosis.PubMedPubMedCentralCrossRef
19.
• Benevento JD, Jager RD, Noble AG, Latkany P, Mieler WF, Sautter M, Meyers S, Mets M, Grassi MA, Rabiah P, Boyer K, Swisher C, McLeod R. Toxoplasmosis-associated neovascular lesions treated successfully with ranibizumab and antiparasitic therapy. Arch Ophthalmol. 2008;126:1152–6 Identifies toxoplasmosis as a cause of choroidal neovascular membranes and their successful treatment with ranibizumab and antiparasitic treatment.PubMedPubMedCentralCrossRef
20.
• Phan L, Kasza K, Jalbrzikowski J, Noble AG, Latkany P, Kuo A, Mieler W, Meyers S, Rabiah P, Boyer K, Swisher C, Mets M, Roizen N, Cezar S, Remington J, Meier P, McLeod R. Longitudinal study of new eye lesions in treated congenital toxoplasmosis. Ophthalmology. 2008;115:553–59 e8 Follows longitudinal outcomes of ocular disease in congenital toxoplasmosis with less recurrence of retinal disease in treated children.PubMedCrossRef
21.
• Phan L, Kasza K, Jalbrzikowski J, Noble AG, Latkany P, Kuo A, Mieler W, Meyers S, Rabiah P, Boyer K, Swisher C, Mets M, Roizen N, Cezar S, Sautter M, Remington J, Meier P, McLeod R. Longitudinal study of new eye lesions in children with toxoplasmosis who were not treated during the first year of life. Am J Ophthalmol. 2008;146:375–84 Follows longitudinal outcomes of ocular disease in congenital. There were more recurrences in children who missed treatment in the first year of life.PubMedPubMedCentralCrossRef
22.
• Jamieson SE, de Roubaix LA, Cortina-Borja M, Tan HK, Mui EJ, Cordell HJ, Kirisits MJ, Miller EN, Peacock CS, Hargrave AC, Coyne JJ, Boyer K, Bessieres MH, Buffolano W, Ferret N, Franck J, Kieffer F, Meier P, Nowakowska DE, et al. Genetic and epigenetic factors at COL2A1 and ABCA4 influence clinical outcome in congenital toxoplasmosis. PLoS One. 2008;3:e2285 Discusses epigenetic influences on the development of congenital toxoplasmosis.PubMedPubMedCentralCrossRef
23.
Jamieson SE, Cordell H, Petersen E, McLeod R, Gilbert RE, Blackwell JM. Host genetic and epigenetic factors in toxoplasmosis. Mem Inst Oswaldo Cruz. 2009;104:162–9 Discusses discovery of susceptibility genes that indicate imprinting and epigenetic influences.
24.
•• Tan T, Mui E, Cong H, Witola W, Montpetit A, Muench S, Sidney J, Alexander J, Sette A, Grigg M, Reed S, Maewal A, Kim S, Boothroyd J, McLeod R. Identification of T. gondii epitopes, adjuvants, & host genetic factors that influence protection of mice & humans. Vaccine. 2010;28:3977–89 Identification of susceptibility gene in NCCCTS cohort, establishing MHC Class I pathway processing by ERAAP. Parts of the initial steps in development of a vaccine to prevent toxoplasmosis in humans which is ongoing with expanded approaches. Demonstration of powerful adjuvant effects of GLA-SE in HLA transgenic mice.
25.
•• Lees MP, Fuller SJ, McLeod R, Boulter NR, Miller CM, Zakrzewski AM, Mui EJ, Witola WH, Coyne JJ, Hargrave AC, Jamieson SE, Blackwell JM, Wiley JS, Smith NC. P2X7 receptor-mediated killing of an intracellular parasite, Toxoplasma gondii, by human and murine macrophages. J Immunol. 2010;184:7040–6 Susceptibility gene for congenital toxoplasmosis which influences outcomes, affecting cytokines and cell death.PubMedCrossRef
26.
Jamieson SE, Peixoto-Rangel AL,Hargrave AC,Roubaix LA,Mui EJ,Boulter NR,Miller EN,Fuller SJ,Wiley JS,Castellucci L, Boyer K, Peixe RG,Kirisits MJ,Elias Lde S,Coyne JJ,Correa-Oliveira R,Sautter M,Smith NC,Lees MP,Swisher CN,Heydemann P,Noble AG,Patel D,Bardo D,Burrowes D,McLone D,Roizen N,Withers S,Bahia-Oliveira LM, McLeod R,Blackwell JM. Evidence for associations between the purinergic receptor P2X(7) (P2RX7) and toxoplasmosis. Genes Immun. 2010;11:374-383. Susceptibility gene for congenital toxoplasmosis which influences outcomes, affecting cytokines and cell death.PubMedPubMedCentralCrossRef
27.
•• Noble G, Latkany P, Kusmierczyk J, Mets M, Rabiah P, Boyer K, Jalbrzikowski J, Wroblewski K, Karrison T, Swisher C, Mieler W, Meier P, McLeod R. Chorioretinal lesions in mothers of children with congenital toxoplasmosis in the National Collaborative Chicago-based, Congenital Toxoplasmosis Study. Scientia Medica. 2010;20:20–6 Finds that ten percent of mothers of infants in the US who have congenital toxoplasmosis have retinal lesions, emphasizing the importance of performing eye examinations of mothers of children with congenital toxoplasmosis.
28.
•• Witola WH, Mui E, Hargrave A, Liu S, Hypolite M, Montpetit A, Cavailles P, Bisanz C, Cesbron-Delauw MF, Fournié GJ, McLeod R. NALP1 influences susceptibility to human congenital toxoplasmosis, proinflammatory cytokine response, and fate of Toxoplasma gondii-infected monocytic cells. Infect Immun. 2011;79:756–66 Identifies susceptibility gene to congenital toxoplasmosis determining functioning of the inflammasome.PubMedCrossRef
29.
Delair E, Latkany P, Noble AG, Rabiah R, McLeod R, Brezin A. Clinical Manifestations of Ocular Toxoplasmosis. Ocul Immunol Inflamm. 2011;2:91–102 Collates and presents clinical manifestations of ocular toxoplasmosis in a pictorial collection.CrossRef
30.
Hill D, Coss C, Dubey JP, Wroblewski K, Sautter M, Hosten T, Munoz-Zanzi C, Mui E, Withers S, Boyer K, Hermes G, Coyne J, Jagdis F, Burnett A, McLeod P, Morton H, Robinson D, McLeod R, Toxoplasmosis Study Group. Identification of a sporozoite-specific antigen from Toxoplasma gondii. J Parasitol. 2011;97:328-37 Identifies antigens in sporozoites in oocysts that elicit an antibody response present for about 8 months following exposure consistent with the half-life of that antibody, allowing exposure. Also identifies high prevalence of Toxoplasma infection in Lancaster Pennsylvania Amish persons.
31.
•• Stillwaggon E, Carrier CS, Sautter M, McLeod R. Maternal serologic screening to prevent congenital toxoplasmosis: a decision-analytic economic model. PLoS Negl Trop Dis. 2011:5–e1333 Demonstrates parameters that lead to cost effective screening for Toxoplasma infection acquired in gestation. This suggests strategies important in this model for lowering costs for diagnosis and treatment to facilitate programs for screening.
32.
•• Boyer K, Hill D, Mui E, Wroblewski K, Karrison T, Dubey JP, Sautter M, Noble AG, Withers S, Swisher C, Heydemann P, Hosten T, Babiarz J, Lee D, Meier P, McLeod R. Toxoplasmosis Study Group. Unrecognized ingestion of Toxoplasma gondii oocysts leads to congenital toxoplasmosis and causes epidemics in North America. Clin Infect Dis. 2011;53:1081–9 Identifies epidemics of acute acquired Toxoplasma infection in North America and that ingestion of oocysts may go unrecognized.
33.
•• McLeod R, Boyer K, Lee D, Mui E, Wroblewski K, Karrison T, Noble AG, Withers S, Swisher CN, Heydemann PT, Sautter M, Babiarz J, Rabiah P, Meier P, Grigg M. Prematurity & Severity Associate with T. gondii Alleles (NCCCTS, 1981-2009). Clin Infect Dis. 2012;54:1595–605 Defines serotypes of T .gondii and their distribution in the United States, and associations of Toxoplasma genotypes with phenotypes of illness including prematurity and severity of illness.
34.
•• Lai BS, Witola WH, El Bissati K, Zhou Y, Mui E, Fomovska A, McLeod R. Molecular target validation, antimicrobial delivery, and potential treatment of Toxoplasma gondii infections. Proc Natl Acad Sci U S A. 2012;109:14182–7 Identification or validation of molecular targets in Toxoplasma and that they can be targeted with antisense as an approach to medicines.
35.
•• Burrowes D, Boyer K, Swisher CN, Noble AG, Sautter M, Heydemann P, Rabiah P, Lee D, McLeod R. Toxoplasmosis Study Group. Spinal Cord Lesions in Congenital Toxoplasmosis Demonstrated with Neuroimaging, Including Their Successful Treatment in an Adult. J Neuroparasitology. 2012;3:1–8 Chronic active toxoplasmosis in an adult and its effective treatment proves that this can occur in the brain and spinal cord, not only the eye, and that it can resolve with treatment.CrossRef
36.
•• Béla SR, Dutra MS, Mui E, Montpetit A, Oliveira FS, Oliveira SC, Arantes RM, Antonelli LR, McLeod R, Gazzinelli RT. Impaired Innate Immunity in Mice Deficient in Interleukin-1 Receptor-Associated Kinase 4 Leads to Defective Type 1 T Cell Responses, B Cell Expansion, and Enhanced Susceptibility to Infection with Toxoplasma gondii. Infect Immun. 2012;80:4298–308 Susceptibility gene and its mechanism in congenital toxoplasmosis.PubMedPubMedCentralCrossRef
37.
•• Witola W, Liu S, Montpetit A, Hypolite M, Zhou Y, Mui E, Cesbron-Delauw MF, Fournie G, Cavailles P, Bisanz C, Boyer K, Withers S, Noble AG, Swisher C, Heydemann P, Rabiah P, McLeod R. ALOX12 In Human Toxoplasmosis. Infect Immun. 2014;82(7):2670–9 Susceptibility genes and their mechanisms in congenital toxoplasmosis.PubMedPubMedCentralCrossRef
38.
• McLeod R. Utility and limitations of T. gondii-specific IgM serum antibodies in the diagnosis of congenital toxoplasmosis in Porto Alegre. J Pediatr. 2014;90(4):329–31 Emphasizes utility and limitation of testing for T.gondii specific IgM serum antibodies in infants.CrossRef
39.
•• McLeod R, Lykins J, Noble AG, Rabiah P, Swisher C, Heydemann P, McLone D, Frim D, Withers S, Clouser F, Boyer K. Management of Congenital Toxoplasmosis. Current Pediatrics Reports. 2014;2(3):166–94 Provides guidelines and an overview of the supporting evidence for the management of congenital toxoplasmosis based on the US experience.CrossRef
40.
•• Hutson SL, Wheeler KM, McLone D, Frim D, Penn R, Swisher CN, Heydemann PT, Boyer KM, Noble AG, Rabiah P, Withers S, Montoya JG, Wroblewski K, Karrison T, Grigg ME, McLeod R. Patterns of Hydrocephalus Caused by Congenital Toxoplasma gondii Infection and Association with Parasite Strain. Cli48, 58,61n Infect Dis. 2015. Pattern of hydrocephalus associated with parasite serotype suggesting different epitopes may be critical or that there may be multifactorial influences.
41.
•• Contopoulos-Ioannidis D, Wheeler KM, Ramirez R, Press C, Mui E, Zhou Y, Van Tubbergen C, Prasad S, Maldonado Y, Withers S, Boyer KM, Noble AG, Rabiah P, Swisher CN, Heydemann P, Wroblewski K, Karrison T, Grigg ME, Montoya JG, McLeod R. Clustering of Toxoplasma gondii Infections Within Families of Congenitally Infected Infants. Clin Infect Dis. 2015;61(12):1815–24 Emphasizes that toxoplasmosis occurs in families, living groups likely exposed to the same risk factors.PubMedPubMedCentralCrossRef
42.
•• McLeod R, Wheeler KM, Boyer K. Reply to Wallon and Peyron. Clin Infect Dis. 2016;62(6):812–4 Emphasizes that favorable outcomes in treated toxoplasmosis are due to treatment.PubMedCrossRef
43.
•• Begeman IJ, Lykins J, Zhou Y, Lai BS, Levigne P, El Bissati K, Boyer K, Withers S, Clouser F, Noble AG, Rabiah P, Swisher CN, Heydemann PT, Contopoulos-Ioannidis DG, Montoya JG, Maldonado Y, Ramirez R, Press C, Stillwaggon E, et al. Point-of-care testing for Toxoplasma gondii IgG/IgM using Toxoplasma ICT IgG-IgM test with sera from the United States and implications for developing countries. PLoS Negl Trop Dis. 2017;11:e0005670 All sera from persons in the NCCCTS including all serotypes and acute, subacute and chronic, could be detected with 100% sensitivity and specificity. A consideration of spillover benefit and clinical benefit is included.
44.
•• Lykins J, Li X, Levigne P, Zhou Y, El Bissati K, Clouser F, Wallon M, Morel F, Leahy K, El Mansouri B, Siddiqui M, Leong N, Michalowski M, Irwin E, Goodall P, Ismail M, Christmas M, Adlaoui EB, Rhajaoui M, et al. Rapid, inexpensive, fingerstick, whole-blood, sensitive, specific, point-of-care test for antiToxoplasma antibodies. PLoS Negl Trop Dis. 2018;12(8):e0006536 Whole blood obtained by fingerstick is an efficient and accurate way to screen for Toxoplasma seropositivity with 100% sensitivity and specificity.PubMedPubMedCentralCrossRef
45.
Lykins J, Wang K, Wheeler K, Clouser F, Dixon A, El Bissati K, Zhou Y, Lyttle C, Rzhetsky A, McLeod R. Understanding Toxoplasmosis in the United States through “Large Data” Analyses. Clin Infect Dis. 2016;63(4):468–75 Initial effort to understand the magnitude and implications of Toxoplasma infection of humans in the United States. Editors choice and Editorial.
46.
• Soberon-Felin M, Grose A, Castro C, Moreira A, AShi K, Li X, McLeod et al. Building Programs to Eliminate Toxoplasmosis: Part II Education. Current Pediatrics Reports 2022. In Press Considers and presents many aspects of contrasts in gestational screening in France facilitating early treatment with delays that are the norm in the United States inxlusing Peyron (2017 see Ref 52).
47.
•• Ngô HM, Zhou Y, Lorenzi H, Wang K, Kim TK, Zhou Y, El Bissati K, Mui E, Fraczek L, Rajagopala SV, Roberts CW, Henriquez FL, Montpetit A, Blackwell JM, Jamieson SE, Wheeler K, Begeman IJ, Naranjo-Galvis C, Alliey-Rodriguez N, Davis RG, Soroceanu L, Cobbs C, Steindler DA, Boyer K, Noble AG, Swisher CN, Heydemann PT, Rabiah P, Withers S, Soteropoulos P, Hood L, Mcleod R. Toxoplasma Modulates Signature Pathways of Human Epilepsy, Neurodegeneration & Cancer. Sci Rep (Nature). 2017;7(1):11496. https://​doi.​org/​10.​1038/​s41598-017-10675-6.​Using a systems biology analysis of genetics, transcriptomics, proteomics, serum and miR biomarkers, upstream regulators, protein association string, immunohistochemistry, and human MM6 (myeloid) and primary human brain neuronal stem cells, disease association analyses, it was found that Toxoplasma modulates signature pathways of human epilepsy, neurodegeneration and cancer. This has important implications for the 2 billion people who have this parasite in their brains across lifetimes, including in Panama, Colombia and the United States, making the seroprevalence of 85% in Panama adults over the age of 65 years potentially of considerable significance for those later in life.CrossRef
48.
•• El Bissati K, Levigne P, Lykins J, Adlaoui EB, Barkat A, Berraho A, Laboudi M, El Mansouri B, Ibrahimi A, Rhajaoui M, Quinn F, Murugesan M, Seghrouchni F, Gómez Marín JE, Peyron F, and McLeod R. Global initiative for congenital toxoplasmosis: an observational and international comparative clinical analysis. Emerging Microbes & Infections (2018) 7:165 Emerging Microbes & Infections 10.1038/s41426-018-0164-4. Introduces the concept of the ongoing global initiative to eliminate toxoplasmosis.
49.
Aguirre AA,Longcore T, Barbieri M, Dabritz H, Hill D, Klein PN,Lepczyk C, Lilly EL, McLeod R, Milcarsky J, Murphy CE, Su C, VanWormer E, Yolken R,Sizemore GC. The One Health Approach to Toxoplasmosis: Epidemiology, Control, and Prevention Strategies. Ecohealth. 2019 10.1007/s10393-019-01405-7. [Epub ahead of print]. Considers Toxoplasma as part of a “One Health” initiative including cat excrement exposure and what could be done to improve water systems and eliminate contamination due to oocysts.
50.
• McLone D, Frim D, Penn R, Swisher CN, Heydemann P, Boyer K, Noble AG, Rabiah P, Withers S, Wroblewski K, Karrison T, Hutson S, Wheeler K, Cohen W, Lykins J, McLeod R. Outcomes of hydrocephalus secondary to congenital toxoplasmosis. J Pediatric Neurosurgery, I doi: 10.3171/2019.6. PEDS18684. 2019. Documents that prompt treatment including needed neurosurgery placement of ventriculoperitoneal shunts can result in favorable outcomes.
51.
• Wallon M, Peyron F, Cornu C, Vinault S, Abrahamowicz M, Kopp CB, Binquet C. Congenital toxoplasma infection: monthly prenatal screening decreases transmission rate and improves clinical outcome at age 3 years. Clin Infect Dis. 2013;56(9):1223–31 Improved outcomes with screening and treatment in utero.PubMedCrossRef
52.
• Peyron F, McLeod R, Ajzenberg D, Contopoulos-Ioannidis DG, Kieffer F, Mandelbrot L, Sibley LD, Pelloux H, Villena I, Wallon M, Montoya JG. Congenital toxoplasmosis in France and the United States: one parasite, two diverging approaches. 2017;11(2):e0005222. France has a strong prenatal diagnosis and treatment program using currently available medicines. This has been initiated but is not yet developed for widespread use in the United States. Currently attempts are initiated to build such programs modeled on the French experience.
53.
•• Prusa AR, Kasper DC, Sawers L, Walter E, Hayde M, Stillwaggon E. Congenital toxoplasmosis in Austria: prenatal screening for prevention is cost saving. PLoS Negl Trop Dis. 2017;11(7):e0005648 Fourteen-fold cost savings, with efficacy that has transformed outcomes of congenital infection in Austria with use of pre-natal screening. Goal herein is to scale up such programs worldwide to benefit individual patients and societies with spill over benefit for maternal and child health.PubMedPubMedCentralCrossRef
54.
Kosack CS, Pasge AL, Klatser PR. A guide to aid the selection of diagnostic tests. Bull World Health Organ. 2017;95(9):639–45 Guide to diagnostic tests prepared by WHO.PubMedPubMedCentralCrossRef
55.
•• Gomez CA, Budvytyte LN, Press C, Zhou L, McLeod R, Maldonado Y, Montoya JG, Contopoulos-Ioannidis DG. Evaluation of three point-of-care (POC) tests for detection of Toxoplasma immunoglobulin IgG and IgM in the United States: proof of concept and challenges. Open For Inf Dis. 2018; 10.1093/ofid/ofy215. High sensitivity and specificity of LDBio used with sera.
56.
•• Stillwaggon E, Carrier CS, Sautter M, McLeod R. Maternal serologic screening to prevent congenital toxoplasmosis: a decision-analytic economic model. PLoS Negl Trop Dis. 2011 ;5(9):e1333. Dec 10(1):1675-1682. doi: 10.1080/22221751.2021.1948359.Supplement. Equations for determining cost efficacy of gestational screening for acquisition of Toxoplasma during gestation. This is to facilitate prompt treatment to prevent congenital infection and/or its sequelae.
57.
• El Mansouri B, Amarir F, Peyron F, Adlaoui EB, Piarroux R, El Abassi M, Lykins J, Nekkal N, Bouhlal N, Makkaoui M, Barkat A, Lyaghfouri A, Zhou Y, Rais S, Daoudi F, Ismail Elkoraichi I, Zekri M, Nezha B, Hajar M, et al. El Bissati K. Performance of a novel point-of-care blood test for Toxoplasma infection in women from diverse regions of Morocco. Microbes Infect. 2021;10(1):1675–82. https://​doi.​org/​10.​1080/​22221751.​2021.​1948359High prevalence of Toxoplasma infection in Morocco: LDBio can be used for diagnosis with high sensitivity and specificity, infection was associated with poverty, well water, not washing fruits and vegetables.
58.
•• Grose A, Wallon M, Chapey E, LeahyK, ZhouY, Siddiqui M, Leong N, Goodall P, Tesic V, Beavis C, Jouze S, Abraham S, Limonne D, Piarroux R, McLeod R. Eliminating Confounding False Positive IGM tests by Using a Lateral Immunochromatography Test that meets WHO ASSURED Criteria In submission, 2022. Demonstrates that LDBio can eliminate problems from false positive IgMs in serologic screening programs for congenital toxoplasmosis for those who are seronegative.
59.
• Flores C, Villalobos-Cerrud D, Borace J, Mcleod R, Fábrega L, Norero X, Sáez-Llorens X, Moreno MT, Restrepo CM, Llanes A, Mario Quijada RM, Ladrón De Guevara M, Guzmán G, de la Guardia V, García A, Wong D, Reyes O, Soberon M, Caballero EZ. Prevalence and risk factors associated with T. gondii infection in pregnant women and newborns from Panama. Pathogens. 2021;10(6):764. https://​doi.​org/​10.​3390/​pathogens1006076​4Identifies areas of high risk in Panama, high frequency of infections, and role of exposure to pet animals.CrossRefPubMedPubMedCentral
60.
•• Mandelbrot L, Kieffer F, Sitta R, Laurichesse-Delmas H, Winer N, Mesnard, Berrebi A, Le Bouar G, Bory J-P, Cordier A-G, Ville Y, Perrotin F, Jouannic J-M, Biquard F, d’ErcoleC, Houfflin-Debarge V, Villena I, Thiébaut R, Prenatal therapy with pyrimethamine + sulfadiazine versus spiramycin to reduce placental transmission of toxoplasmosis: A multicenter, randomized trial, American Journal of Obstetrics and Gynecology (2018), 10.1016/j.ajog.2018.05.031. Demonstrates that outcomes can be highly favorable with serologic screening in gestation and prompt treatment, with slight improvement in outcomes with pyrimethamine and sulfadiazine treatment after 16 weeks gestation defined as 16 weeks of amenorrhea.
61.
McLeod R., Sautter M, Rooney T, Morel J, Taub L, Taub D, Taub V, Taub JW, Tirado S, Latkany P, Boyer K, Hotez P, Lin E, McLone D, and Friends et al Submission to the Committee on Public Health Illinois State Senate. Regarding: Prenatal and Neonatal Congenital Toxoplasmosis Prevention and Treatment Act, SB3667 in the context of the National Collaborative Chicago Based Congenital Toxoplasmosis Study. April 13, 2010. Introduction of a bill to have a law that obstetricians in Illinois offer their patients the opportunity to have serologic testing in gestation, in Illinois. This provided information from patients, families, physicians, scientists. Recommended law.
62.
•• Dubey JP, Murata FHA, Cerqueira-Cézar CK, Kwok OCH, Villena I. Congenital toxoplasmosis in humans: an update of worldwide rate of congenital infections. Parasitology. 2021;148:1406–16. https://​doi.​org/​10.​1017/​S003118202100101​3Up to date review of prevalence and findings of congenital toxoplasmosis around the world.
63.
• Gomez-Marín JE, Munoz-Ortiz J, Mejía-Oquendo M, Arteaga-Rivera JY, Nicolas Rivera-Valdivia N, Bohorquez-Granado MC, Velasco-Velasquez S, Castano-de-la-Torre G, Acosta-Davila JA, García-Lopez LL, Torres-Morale ES, Vargas M, Valencia JD, Celis-Giraldo D, de-la-Torre A. High frequency of ocular toxoplasmosis in Quindío, Colombia and risk factors related to the infection. Heliyon. 2021;7:e06659 Identifies high prevalence of ocular toxoplasmosis in Quindio, Colombia and associated risk factors. Importance of water purification (drinking bottled water) associated with prevention was identified.PubMedPubMedCentralCrossRef
64.
•• McLeod R.,Cohen W, Dovgin S, Finkelstein L, Boyer K. Human Toxoplasmosis. Weiss, LM, Kim, K. (Editors). The Model apicomplexan: Perspectives and Methods Third Edition. Chapter 4. Elsevier.2020 pp.117-228. Comprehensive up to date consideration of human toxoplasmosis, including clinical aspects, treatment, prevention, other considerations of pathogenesis, unifying concepts and toward the future.
65.
Mejia-Oquendo M, Marulanda-Ibarra E, Gomez-Marin JE, Evaluation of the impact of the first evidence-based guidelines for congenital toxoplasmosis in Armenia (Quindío) Colombia: An observational retrospective analysis The Lancet Regional Health - Americas.2021;1:100010. Between 2001 and 2019, national guideline has had a positive impact by improv-ing early diagnosis and treatment of prenatal toxoplasmosis and reducing severity.'.
66.
•• Kieffer F, Wallon M, Garcia P, Thulliez P, Peyron F, Franck J. Risk factors for retinochoroiditis During the firat 2 years of life in infants with treated Congenital toxoplasmosis. J Pediatr Infect Dis J. 2008;27(1):27–32. https://​doi.​org/​10.​1097/​INF.​0b013e318134286d​Defines risk factors for active disease in the first two years of life in children with treated congenital disease. “3 factors were significantly associated with first retinochoroiditis before the age of 2 years: a delay of >8 weeks between maternal seroconversion and first treatment [hazard ratio, 2.54; 95% confidence interval (CI), 1.14-5.65], female gender (hazard ratio, 2.02; 95% CI, 1.01-4.1), and cerebral calcifications at birth (hazard ratio, 4.3; 95% CI, 1.9-10). There was no correlation between gestational age at the time of maternal infection and risk for retinochoroiditis.”.CrossRefPubMed
67.
•• Soberon-Felin, McLeod et al. Building Programs to eradicate Toxoplasmosis. Part IV:: Understanding and Development of Public Health Strategies and Advances “Takea Village”. Current Pediatrics Reports. 2022 In Press Considers needed next stesps in a global initiative to eradicate Toxoplasosis. Considers Wallon (51).
68.
•• Montoya JG, Laessig K, Fazeli MS, Siliman G, Yoon SS, Drake-Shanahan E, Zhu C, Akbary A, Mcleod R. A fresh look at the role of spiramycin in preventing a neglected disease: meta-analyses of observational studies. Eur J Med Res. 2021;26(1):1–0 Meta-analysis shows contribution of spiramycin to prevention and improved outcomes of congenital toxoplasmosis. Recent work by Mandelbrot et al suggests its most important role is in the first 14 weeks of gestation trimester when pyrimethamine may be teratogenic.CrossRef
69.
McLeod R, Lee D, Clouser F, Boyer K. Toxoplasmosis in the Fetus and Newborn Infant. In: Stevenson D and Sunshine P, Neonatology: Clinical Practice and Procedures. 1st, New York: McGraw Hill; 2015. p. 821–76. Comprehensive review of data concerning toxoplasmosis in the fetus and newborn infant with images.
70.
McLeod R, Lee D, Clouser F, Boyer K. Diagnosis of Congenital Toxoplasmosis. In: Stevenson D and Sunshine P, Neonatology: Clinical Practice and Procedures. 1st, New York: McGraw Hill; 2015. p. 1297–310. Atlas of images of congenital toxoplasmosis and its diagnosis and treatment.
71.
•• McLeod R, Boyer K. Toxoplasmosis. In Nelson’s Textbook of Pediatrics, 22ndt Ed. Behrman RL, Kliegman R, Arvin AM (Eds.). Philadelphia, WB Saunders, 2021. In Press. Most current chapter summarizing newer aspects of Toxoplasmosis in 2021.
72.
•• Remington JS, McLeod R, Thulliez P, Desmonts G, Toxoplasmosis. Infectious Diseases of the Fetus and Newborn Infant. Ch 31. Elsevier. 6th edition. 2006. pp.947-1091. Detailed, thorough chapter that presents data and images of toxoplasmosis in the fetus and newborn infant.
73.
•• Hotez PJ. Neglected Infections of Poverty in the United States of America P. June 2008 | Volume 2 | Issue 6 | e2 PLoS Neglected Tropical Diseses 2008. Demonstrates and emphasizes that the diseases noted to occur in developing countries also occur in the United States, especially in areas of poverty. These include toxoplasmosis, which affects persons of all demographics.
74.
•• Lago EG, Endres MM, MFDC S, Fiori HH. Ocular Outcome of Brazilian Patients with Congenital Toxoplasmosis. Pediatr Infect Dis J. 2021;40(1):e21–7. https://​doi.​org/​10.​1097/​INF.​0000000000002931​Part of a series of papers by Lago et al, demonstrating the severity of congenital toxoplasmosis in Brazil, manifestations, and efficacy associated with the high incidence of new retinochoroidal lesions during the follow-up period indicates the importance of long-term follow-up of patients with congenital toxoplasmosis. Initiating treatment within the first 4 months of life, especially within the first 2 months, was a protective factor against the later development of retinochoroiditis.CrossRefPubMed
75.
•• Silva Machado A et al. Biomarker Analysis Revealed Distinct Profiles of Innate and Adaptive immunity in Infants with ocular lesions of Congenital toxoplasmosis Scientific Reports, vol 2014, 2020. Active retinal lesions associated with leukocytosis with monocytes and NK cells CD8+ T cells, possibly predicting morbidity.
76.
Guerina NG, Hsu HW, Meissner HC, et al. Neonatal serologic screening and early treatment for congenital Toxoplasma gondii infection. The New England Regional Toxoplasma Working Group. N Engl J Med. 1994:330–1858 Newborn screening program in Massachusetts, New Hampshire and Vermont detects congenital toxoplasmosis not otherwise recognized at birth with approximately half with retinal or central nervous system signs with careful evaluation.
77.
Dubey JP, Lago EG, Gennari SM Su, Jones JL. Toxoplasmosis in humans and animals in Brazil: high prevalence, high burden of disease, and epidemiology. Parasitology. 10 July 2012. Comprehensive review of toxoplasmosis in Brazil.
78.
Chapey, E., Wallon, M., Peyron, F., 2017. Evaluation of the LDBIO point of care test for the combined detection of toxoplasmic IgG and IgM. Clin. Chim. Acta 464,200-201. Available from: https://​doi.​org/​10.​1016/​j.​cca.​2016.​10.​023. Lateral immunochromatography test for IgG and IgM sensitive and specific in France when testing serum.
79.
•• Pomares C, Zhang B, Arulkumar S, Gonfrier G, Marty P, Zhao S, Cheng S, Tang M, Dai H, Montoya JG. Validation of IgG, IgM multiplex plasmonic gold platform in French clinical cohorts for the serodiagnosis and follow-up of Toxoplasma gondii infection. Diagn Microbiol Infect Dis. 2017;87(3):213–8. https://​doi.​org/​10.​1016/​j.​diagmicrobio.​2016.​09.​001Inexpensive serum and saliva nanotest diagnoses Toxoplasma infection.
80.
•• Li X, Pomares C, Peyron F, Press CJ, Ramirez R, Gonfrier G, Cannavo I, Chapey E, Levigne P, Wallon M, Montoya JG, Hongjie Dai H. Plasmonic gold chips for the diagnosis of Toxoplasma gondii, CMV, and rubella infections using saliva with serum detection precision. Eur J Clin Microbiol Infect Dis. 2019;38(5):883–90. https://​doi.​org/​10.​1007/​s10096-019-03487-1Nanogold test can be multiplexed for perinatal infections with high sensitivity and specificity.CrossRefPubMed
81.
•• Abraham S, McLeod R, Houhou-Fidouh, Nicaise-Rolland P, Landraud L, Houze S. Performances of Toxoplasma ICT IgG-IgM in comparison with Vidas Toxo Competition and Toxoscreen, Lyon France European meeting. 2022. In submission. Lateral Chromatography test highly sensitive and specific when testing sera from persons in France and the USA.
82.
Ben-Abdallah R et al. Contribution of the Toxoplasma ICT IgG IGM test in determining the immune status of pregnant women against toxoplasmosis. 10.1002/jcla 23749 2021. Lyon France European meeting. ICT Lateral immunochromatography test sensitive and specific with sera in Algeria.
83.
Cardosa L, Piarroux R, Lopes APInterest du test Toxoplasma ICT IgG-IgM dans le diagnostic serologique de l’infection a Toxoplasma gondi chez le chat. 2022. In Press. POC test also of use for detection of infection in cats although not as sensitive and specific as for human infections.
84.
•• McPhillie M, Zhou Y, El Bissati K, Dubey J, Lorenzi H, Capper M, Lukens AK, Hickman M, Muench S, Verma SK, Weber CR, Wheeler K, Gordon J, Sanders J, Moulton H, Wang K, Kim TK, He Y, Santos T, et al. New paradigms for understanding and step changes in treating active and chronic, persistent apicomplexan infections. Sci Rep. 2016;6:29179. https://​doi.​org/​10.​1038/​srep29179Brazilian strain of Toxoplasma, EGS, grows as a slowly replicating encysted organism in tisuue culture identifying cytochrome b qi domain as critical for this lifecycle stage. This is used to develop an inhibitor of this molecular target in Toxoplasma amd Plasmodia.CrossRefPubMedPubMedCentral
85.
•• McPhillie M, Zhou Y, Hickman M, Gordon J, Weber C, Li Q, Lee P, Amporndanai K, Johnson RH, Darby H, Woods S, Li ZH, Priestley R, Ristroph K, Biering GC, El Bissati K, Hwang S, Hakim FE, Dovgin S, et al. Potent Tetrahydroquinolone Eliminates Apicomplexan Parasites. Front. Cell Infect Microbiol. 2020;10:203. https://​doi.​org/​10.​3389/​fcimb.​2020.​00203JAG21 is potent against tachyzoites, bradyzoites of toxoplasma, completely curative with prompt treatment. If begun in vivo after 15 days in vivo a small proportion of cysts (<50%) remain. Effective at low nM amounts in single oral dose also against P berghei three life cycle stages. “Persister” of a model parasite rps 13 delta that has exited the cell cycle shows overlapping molecular targets with P. cynomogoli hypnozoites single cell RNA seq providing insight into and model system to test which genes are transcribed in the small numbers of persisters.CrossRef
86.
•• E book, Research Topic editorial: Front. Cell. Infect. Microbiol. McPhillie M, Zhou Y, Hickman M, Gordon J, Weber C, Li Q, Lee P, Amporndanai K, Johnson RH, Darby H, Woods S, Li ZH, Priestley R, Ristroph K, Biering GC, El Bissati K, Hwang S, Hakim FE, Dovgin S, Lykins J, Roberts L, Hargrave K, Cong H, Sinai A, Muench SP, Dubey JP, Prud’homme R, Lorenzi, H Biagini GC, Moreno S, Roberts CW, Atonyuk S, Fishwick CW and McLeod R (2020) Potent Tetrahydroquinolone Eliminates Apicomplexan Parasites. Front. Cell. Infect. Microbiol Ebook with editorial by de-la-Torre A and Gomez-Marin JE that states: “Finally, one major finding reported in this Research Topic is the development of a powerful tetrahydroquinolone, JAG21, which can eliminate apicomplexan parasites in tissues (McPhillie et al.). This is an extraordinary achievement in in vivo models because, until now, there are no drugs that can eliminate tissue cysts of the parasite responsible for reactivations during the host’s period of life. The authors created a next generation lead compound with high in vitro and in vivo efficacy against T. gondii tachyzoites, bradyzoites, and established encysted organisms (McPhillie et al). This compound is promising and deserves further development through preparation of advanced formulations and testing in further studies of pharmacokinetics, efficacy, and safety. In summary, this Research Topic shows significant advances made in the study of T. gondii using in-vitro, in-vivo and animal models. The results presented here will illuminate the pathway to create an effective clinical response to this public health key issue.”
87.
Lykins JD, Filippova EV, Halavaty AS, Minasov G, Zhou Y, Dubrovska I, Flores KJ, Shuvalova LA, Ruan J, El Bissati K, Dovgin S, Roberts CW, Woods S, Moulton JD, Moulton H, McPhillie MJ, Muench SP, Fishwick CWG, Sabini E, et al. CSGID Solves Structures and Identifies Phenotypes for Five Enzymes in Toxoplasma gondii. Front Cell Infect Microbiol. 2018;8:352. https://​doi.​org/​10.​3389/​fcimb.​2018.​00352.​ eCollection 2018 Crystalography pipeline identifies potential molecular targets (enzymes) in Toxoplasma gondii; Vivo morpholinos and CRISPR/Cas9 screen together demonstrate which is essential in tachyzoites.CrossRefPubMedPubMedCentral
88.
Eichenwald HF. A study of congenital toxoplasmosis with particular emphasis on clinical manifestations, sequelae and therapy. In: Human Toxoplasmosis, Siim JC (Ed), Munksgaard, Copenhagen 1959. Congenital toxoplasmosis with generalized or neurologic presentation in the US if untreated or treated only one month causes substantial neurologic and eye disease by the age of 4 years with significant morbidity.
89.
Koppe JG, Loewer-Sieger DH, de Roever-Bonnet H. Results of 20-year follow-up of congenital toxoplasmosis. Lancet. 1986;1:254 Apparently asymptomatic infants develop adverse visual sequelae of congenital toxoplasmosis by teensge years.PubMedCrossRef
90.
Wilson CB, Remington JS, Stagno S, Reynolds DW. Development of adverse sequelae in children born with subclinical congenital Toxoplasma infection. Pediatrics. 1980;66:767 Apparently asymptomatic infants develop adverse retinal and central nervous system sequelae of congenital toxoplasmosis.PubMedCrossRef
91.
92.
Ryning FW, Mcleod R, Maddox JC, Hunt S, Remington JS. Probable transmission of Toxoplasma gondii by organ transplantation. Ann Intern Med. 1979;90(1):47–9 Patient who received a cardiac transplant donated from a person who died in a motorcycle accident who had acute toxoplasmosis. The recipient of this infected donor organ developed brain abscesses and encephalitis due to Toxoplasma gondii. His toxoplasmic brain disease responded to many months of treatment with pyrimethamine, sulfadiazine and leucovorin demonstrating this infection could be treated in such immune compromised persons when treatment was continued throughout the immune compromise until resolution of brain involvement.PubMedCrossRef
93.
Levin M, Mcleod R, Young Q, Abrahams C, Chambliss M, Walzer P, Kabins SA. Pneumocystis pneumonia: importance of gallium scan for early diagnosis and description of a new immunoperoxidase technique to demonstrate Pneumocystis carinii. Am Rev Respir Dis. 1983;128(1):182–5 Initial patient with toxoplasmosis encephalitis in the Midwest and eleventh in the United States with multiple opportunistic infections at the outset of the AIDS epidemic. His toxoplasmic encephalitis responded to treatment with pyrimethamine sulfadizine given with leucovorin.
94.
Dubey JP. Schizogony and gametogony of oocyst-deficient T-263 strain of Toxoplasma gondi. Vet Parasitol. 2017;245:160–2. https://​doi.​org/​10.​1016/​j.​vetpar.​2017.​05.​024T-263 cannot make life cycle stages beyond schizonts, male and female gametes. This chemically mutagenized parasite clone is an effective accine when administered orally in separate study eliminating endemic toxoplasmic infections on a pig farm in southern Illinois when administered to cats on this farm. Subsequent analysis of this clone provides a rosetta stone to merozoite development and capacitation preparing for Conception of Toxoplasma gondii.CrossRefPubMed
95.
Ramakrishnan C, Maier S, Walker R et al. An experimental genetically attenuated live vaccine to prevent transmission of Toxoplasma gondii by cats. Scientific Reports vol 9, No.: 1474 (2019) “RNA-Seq analysis of cat enteric stages of T. gondii uncovered genes expressed uniquely in microgametes and macrogametes. A CRISPR/Cas9 strategy was used to create a T. gondii strain that exhibits defective fertilization, decreased fecundity and generates oocysts that fail to produce sporozoites. Inoculation of cats with this engineered parasite strain totally prevented oocyst excretion following infection with wild-type T. gondii, demonstrating that this mutant is an attenuated, live, transmission-blocking vaccine.”
96.
Alvarez C, de-la-Torre A, Vargas M, Herrera C, Uribe-Huertas LD, Lora F, and Gómez-Marín JE Striking Divergence in Toxoplasma ROP16 Nucleotide Sequences From Human and Meat Samples. JID 2015:211 (15 June). p2006. Association of Rop 16 type 1/3 variant with ocular toxoplasmosis in Colombia demonstrated by sequence and peptide elisa testing of sera is not the predominant organism found in meat samples. Variation in storage processes and hygenic factors differed in stores selling meat in Quindio, Armenia Colombia.
97.
Hutson SL, Mui E, Kinsley K, Witola WH, Behnke MS, El Bissati K, Muench SP, Rohrman B, Liu SR, Wollmann R, Ogata Y, Sarkeshik A, Yates JR 3rd, McLeod RT. T. gondii RP promoters & knockdown reveal molecular pathways associated with proliferation and cell-cycle arrest. PLoS One. 2010;5:e14057 Gi arrested tetracycline regulated mutant RH strain parasite is a dormant persisting parasite when tetracycline regulating and leading to transcription of the the small ribosomal protein 13 (RPS13) gene is absent. This organism can recrudesce after very long times in tissue culture exceeding 6-months demonstrating effect of ribosomal stress secondary to protein starvation. This mutated parasite is a highly effective vaccine for mice.
98.
99.
•• De Mourn L, Garcia Bahia-Oliveira, Lilian Maria. Wada MY, Jeffrey L. Jones, Suely H. Tuboi, Eduardo H. Carmo, Walter Massa Ramalho, Natal J. Camargo, Ronaldo Trevisan, Regina M. T. Graça, Alexandre J. da Silva, Iaci Moura, J.P. Dubey, and Denise O. Garrett. Waterborne Toxoplasmosis, Brazil, from Field to Gene. Emerg Infect Dis 2006 Feb; 12(2): 326–329. doi: 10.3201/eid1202.041115 . Waterborn epidemics of toxoplasmosis in Brazil.
100.
•• McLeod R, Frenkel JK, Estes RG, Cohen H, Mack DG, Eisenhauer PB, Gibori G. Subcutaneous and intestinal vaccination with tachyzoites of Toxoplasma gondii and acquisition of immunity to peroral and congenital toxoplasma challenge. J Immunol. 1988;140(5):1632–7 Live vaccine and model to protect against Toxoplasma infection in mice.
101.
El Bissati K, Zhou Y, Paulillo S, Raman SK, Karch C, Roberts CW, Burkhard P, McLeod R. Novel protein nanovaccine confers robust immunity against Toxoplasma. Nature (NPJ) Vaccines. 2017;2:24. https://​doi.​org/​10.​1038/​s41541-017-0024-6Self-assembling nanoparticle vaccine created using immunosense priciples creates a powerful vaccine tailored to protect humans but the principles can also incorporated full length proteins effective for immunizing other species.CrossRefPubMedCentral
102.
Zhou Y. Melo M, Weiss R, El Bissati K, Irvine D, McLeod R, RNA replicon vaccines protect against toxoplasmosis. Immunosense and SAG1 in a noel SAPN vaccine with a new Toxoplasma CD4 eliciting peptide. 2022. In preparation. RNA replicons created using immunosense principles effectively immunize against T. gondii but SAG1 is most critical when combined with RNA encoding the peptides, emphasizing importance of SAG1 as an immunogen in future vaccines.
103.
Zhou Y, El Bissati K, Reed S, Fox C, Alexander J, Sidney J, Sette A, Burkhard P, McLeod R. Adjuvanting designer SAPN vaccines with conventional adjvuants demonstrates superiority of GLA-SE and inability to combine the adjuvant CPG and GLA-SE. Designer vaccines to protect humans against toxoplasmosis cannot be adjuvanted with cpg and gla-se together but are effective with one or the other adjuvants.
104.
Waldman, B.S., Schwarz, D., Wadsworth, M.H., Saeij, J.P. Shalek, A.K., Lourido, S., 2019. Identification of a master regulator of differentiation in Toxoplasma. BioRxiv660753. Available from: https://​doi.​org/​10.​1101/​660753. Regulator of bradyzoite stage switch discovered.
105.
Elbissati K, Raczy M, ZhouY, Weber C, Solaki A, Reed S, Fox C, Alexander J, Sidney J, Sette A, Burkhard P, Hubbel J, McLeod R. In preparation 2022. Creation of a “plug and play” strategy to create designer vaccines to protect humans and other species. GLA-se and immunosense SAPN create a potent vaccine against toxoplasmosis in HLA transgenic mice.
106.
Chalal JS, et al Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondiichallenges with a single dose 2016 Jul 5. https://​doi.​org/​10.​1073/​pnas.​1600299113 PMCID: PMC4961123 PMID: 27382155. Venezuelan Equine Virus (VEEV)-based modified dendrimer nanoparticle RNA (MDNP RNA) vaccine protects against death due to Pru with HGXPRT strain Toxoplasma gondii. RNA replicons encoding full length SAG1, SAG2A, AMA1, GRA6, ROP2A, and ROP18, protect C57Bl6 mice for 175 days post challenge against this strain when replicon is incorporated in polyethylene glycol lipid nanoparticle.
107.
Lai B-S, Witola WH, Bissati K, El Zhou Y, Mui E, et al. Molecular target validation, antimicrobial delivery, and potential treatment of Toxoplasma gondii infections. Proc Natl Acad Sci U S A. 2012;109(35):1418214187 Peptide or vivo morpholinos targeting essential parasite molecules such as DHFR, ENR, and Apetela 2 transcription factors can treat toxoplasma infection.CrossRef
108.
Tipparaju SK, Muench SP, Mui EJ, Ruzheinikov SN, Lu JZ, Hutson SL, Kirisits MJ, Prigge ST, Roberts CW, Henriquez FL, Kozikowski AP, Rice DW, Mcleod RL. Identification and development of novel inhibitors of Toxoplasma gondii enoyl reductase. J Med Chem. 2010;53:6287–300 Novel inhibitors of toxoplasma type ii fatty acid synthesis can treat toxoplasmosis.PubMedPubMedCentralCrossRef
109.
Mazumdar JH, Wilson E, Masek KA, Hunter C, Striepen B. Apicoplast fatty acid synthesis is essential for organelle biogenesis and parasite survival in Toxoplasma gondii. Proc Natl Acad Sci U S A. 2006;103:13192–7 Type 2 fatty acid synthesis (fas) is essential for parasite survival and organelle biogenesis.PubMedPubMedCentralCrossRef
110.
Welsch ME, Zhou J, Gao Y, Yan Y, Porter G, Gautam Agnihotri G, Yingjie Li YM, Lu H, Chen Z, Thomas SB. Discovery of Potent and Selective Leads against Toxoplasma gondii Dihydrofolate Reductase via Structure-Based Design. ACS Med Chem Lett. 2016, 7(12):1124–9. https://​doi.​org/​10.​1021/​acsmedchemlett.​6b00328Targeting Toxoplasma DHFR creates a potent inhibitor of T. gondii tachyzoites currently held by Vyera.
111.
Mui EJ, Schiehser GA, Milhous WK, Hsu H, Roberts CW, Kirisits M, Muench S, Rice D, Dubey JP, Fowble JW, Rathod PK, Queener SF, Liu SR, Jacobus DP, McLeod R. Novel Triazine JPC-2067-B Inhibits Toxoplasma gondii In Vitro and In Vivo. PLoS Negl Trop Dis. 2008;2:e190 Novel triazine is a potent inhibitor nanomolar inhibitor of T. gondii tachyzoites as effective as a single anti-parasitic ompound as pyrimethamine and sulfadiazine acting synergistically together.PubMedPubMedCentralCrossRef
112.
Samuel BU, Hearn B, Mack D, Wender P, Rothbard J, Kirisits MJ, Mui E, Wernimont S, Roberts CW, Muench SP, Rice DW, Prigge ST, Law AB, McLeod R. Delivery of antimicrobials into parasites. Proc Natl Acad Sci U S A. 2003;100:14281–6 Transductive peptides can deliver small molecules into tachyzoites and encysted bradyzoites creating potent inhibitors of T. gondii.PubMedPubMedCentralCrossRef
113.
Zhou Y, Fomovska A, Muench S, Lai BS, Mui E, Mcleod R. Spiroindolone that inhibits PfATPase4 is a Potent, Cidal Inhibitor of Toxoplasma gondii tachyzoites in vitro and in vivo. Antimicrob Agents Chemother. 2014;58(3):1789-92. Spiroindolone that inhibits ATPase 4 is a cidal inhibitor of T. gondii tachyzoites. VivoPMO also is effective.
114.
Fomovska A, Huang Q, El Bissati K, Mui EJ, Witola WH, Cheng G, Zhou Y, Sommerville C, Roberts CW, Bettis S, Prigge ST, Afanador GA, Hickman MR, Lee PJ, Leed SE, Auschwitz JM, Pieroni M, Stec J, Muench SP, et al. Novel N-benzoyl-2-hydroxybenzamide disrupts unique parasite secretory pathway. Antimicrob Agents Chemother. 2012;56:2666–82. https://​doi.​org/​10.​1128/​AAC.​06450-11Small molecule screen identifies a hydroxybenzamide that disrupts the T. gondii secretory pathway creating a potent inhibitor.CrossRefPubMedPubMedCentral
115.
Smith D et al Toxoplasma TgATG9 is critical for autophagy and long-term persistence in tissue cysts eLife Apr 27, 2021. Autophagy protein TgATG9 is critical for long term persistence of T. gondii cysts.
116.
Khan I, Huang et al. CD8 T cells cry for help. Front Cell Infect Microbiol. 2019;9:136. https://​doi.​org/​10.​3389/​fcimb.​2019.​00136 BLIMP regulates 41BB mediated exhaustion of T cells that can be corrected by agonist antibody to 41BB. This eliminates encysted organisms which could make it possible to eliminate remaining tahyzoites by waking up protective immunologic mechanisms and targeting tachyzoites.
117.
•• Souza SP, Splitt SD, Alvarez JA, Wizzard S, Wilson JN, Luo Z, Baumgarth N, Jensen, KDC NFkBid is required 1 for immunity and antibody responses to Toxoplasma gondii bioRxiv preprint https://​doi.​org/​10.​1101/​2020.​06.​26.​174151. A “collaborative cross” of mice demonstrates that hypervirulent South American parasite escapes protective immunological mechanisms effective against Type I, II, III parasites. Bumble mice with a difference in NFkBid also are not protected. These studies demonstrate the importance of NKcells and specific isotypes of antibody in protection against toxoplasmosis.
118.
Borrmann S, Peter G. Kremsner PG et al. Fosmidomycin plus Clindamycin for Treatment of Pediatric Patients Aged 1 to 14 Years with Plasmodium falciparum Malaria. Antimicrobial Agents and ChemotherapyVolume 50, Issue 8, August 2006, Pages 2713-2718 https://​doi.​org/​10.​1128/​AAC.​00392-06. Inhibitor of mevalonate pathway discovered by Jomaa and Soldati inhibits Toxoplasma and Plasmodia. When administered with clindamycin, a delayed acting inhibitor is effective but has hematologic toxicity in humans.
119.
Ismael AB, Dimier-Poisson I, Lebrun M, Dubremetz JF, Bout D, Mévélec MN. Mic1-3 knockout of Toxoplasma gondii is a successful vaccine against chronic and congenital toxoplasmosis in mice. J Infect Dis. 2006;194(8):1176–83 Knockout of microneme proteins creates live attenuate organism that functions well to protect mice against toxoplasmosis including congenital infection.PubMedCrossRef
120.
•• Dimier-Poisson I, Carpentier R, Nguyen T, Dahmani F, Ducournau C, Betbeder D. Porous nanoparticle as delivery system of complex antigens for an effective vaccine against acute and chronic Toxoplasma gondii infection. Biomaterials. Remarkable formulation of RH parasite lysate in a nanoparticle administered intranasally protects mice, sheep and primates in a zoo ending an epidemic of deaths due to toxoplasmosis in susceptible new world primate colonies in zoos across France. Creation of a vaccine capable of protecting multiple species of mammals. Remarkable protection with practical proof in French zoos for primates.
121.
•• El Bissati K, Roberts CW, McLeod R. Adjuvanted multi-epitope vaccines protect HLA-A*11:01 transgenic mice against Toxoplasma gondii. JCI Insight. 2016;1(15):e85955. https://​doi.​org/​10.​1172/​jci.​insight.​85955Combining T. gondii peptides mapped as important in immunosense system studies against toxoplasmosis in HLA Class I transgenic mice are potent as a polypeptide vaccine when admistered to these mice combined with a universal peptide eliciting CD4+T cells and GLA-SE a nanoemulsion adjuvant now in clinical use that stimulates TLR4.
122.
•• Lourido, S., Jeschke, G.R., Turk, B.E., Sibley, L.D., 2013.Exploiting the unique ATP-binding pocket of toxoplasmacalcium-dependent protein kinase 1 to identifyits substrates. ACS Chem Biol. 8 (6), 1155-1162. Available from: https://​doi.​org/​10.​1021/​cb400115y. Calcium dependent protein kinases are molecular targets in tachyzoite and encysted bradyzoites leading to development of small molecule inhibitor “lead compound” currently held by Vyera.
123.
•• Karanovic D, Michelow IC, Hayward AR, DeRavin SS, Delmonte OM, Grigg ME, Dobbs AK, Niemela JE, Stoddard J, Alhinai Z, Rybak N, Hernandez N, Pittaluga S, Rosenzweig SD, Uzel G, Notarangelo LD. Disseminated and Congenital Toxoplasmosis in a Motherand Child with Toxoplasma Infections in Primary Immunodeficiencies. Front Immunol. 2019;10:77. https://​doi.​org/​10.​3389/​fimmu.​2019.​0007Summarizes and identifies genes and pathways in which they function where mutations confer susceptibility to human toxoplasmosis.
124.
•• Naranjo-Galvis CA, de-la-Torre A, Mantilla-Muriel LE, Beltrán-Angarita L, Elcoroaristizabal-Martín X, McLeod R, Alliey-Rodriguez N, Begeman IJ, López de Mesa C, Gómez-Marín JE, Sepúlveda-Arias JC. Genetic Polymorphisms in Cytokine Genes in Colombian Patients with Ocular Toxoplasmosis. Infect Immun. 2018;86(4):e00597-17. https://​doi.​org/​10.​1128/​IAI.​00597-17Identifies the importance of cytokine genes in protection against toxoplasmosis in Colombia.
125.
•• Perce-da-Silva, D de Souza, Thays Euzebio J; Aleixo, Quintella do CoutoAL; Motta J; Ribeiro-Alves, M; Oliveira Ferreira, J de; Porto, Cristóvão de Moraes Sobrino L; Banic DM; Reis Amendoeira MR Influence of Activating and Inhibitory Killer Immunoglobulin-Like Receptors (KIR) genes on the recurrence rate of ocular toxoplasmosis in Brazil. BioRx. https://​doi.​org/​10.​1101/​2020.​09.​16.​299446; Identifies natural killer cell receptors in protection against recurrence of ocular toxoplasmosis in humans in Brazil.
126.
•• Roberts F, Roberts CW, Johnson JJ, Kyle DE, Krell T, Coggins JR, Coombs GH, Milhous WK, Tzipori S, Ferguson DJ, Chakrabarti D, McLeod R. Evidence for the shikimate pathway in apicomplexan parasites. Nature. 1998;393:801–5 Plant-like metabolic pathways in apicomplexan parasites can be targeted. Apicomplexan parasites are mosaics of metabolic pathways identifying unique ways to target organellar and cytoplasmic pathways.
127.
•• Zuther E, Johnson JJ, Haselkorn R, McLeod R, Gornicki P. Growth of Toxoplasma gondii is inhibited by aryloxyphenoxypropionate herbicides targeting acetyl-CoA carboxylase. Proc Natl Acad Sci U S A. 1999;96:13387–92 Targetting the plant-like acetyl-CoA carboxylase with herbicides known to inhibit this enzyme in weeds identifies two classes of small molecules capable of inhibiting apicomplexan parasites through targeting enzymes stored in the chloroplast like organelle inherited from an ancient progenitor Copydelia demonstrating this plant-like endosymbiotic organelle can be targeted. This suggests the possibility of targeting other unique organellar constituents and phylogenetically genetically distinct molecules including plant-like transcription factors as in McPhillie reference above as “Achilles heels” where these parasites are susceptible to unique methods of inhibiting these parasites.
128.
•• Doggett JS, Nilsen A, Forquer I, Wegmann KW, Jones-Brando L, Yolken RH, Bordón C, Charman SA, Katneni K, Schultz T, Burrows JN, Hinrichs DJ, Meunier B, Carruthers VB, Riscoe MK. Endochin-like quinolones are highly efficacious against acute and latent experimental toxoplasmosis. Proc Natl Acad Sci U S A. 2012;109:15936–41. https://​doi.​org/​10.​1073/​pnas.​1208069109Effect of endochin-like quinolomes against cytochrome bc in Toxoplasma inhibits encysted bradyzoites in mouse models although inhibition is not complete.
129.
•• Kortagere S, Mui E, McLeod R, Welsh WJ. Rapid discovery of inhibitors of Toxoplasma gondii using hybrid structure-based computational approach. J Comput Aided Mol Des. 2011;25:403–11. https://​doi.​org/​10.​1007/​s10822-011-9420-6Targeting Myosin in Toxoplasma and using a computational approach with medicinal chemistry creates an inhibitor of Toxoplasma tachyzoites.
130.
131.
•• Dando C, Schroeder ER, Hunsaker LA, Deck LM, Royer RE, Zhou X, Parmley SF, Vander Jagt DL. The kinetic properties and sensitivities to inhibitors of lactate dehydrogenases (LDH1 and LDH2) from Toxoplasma gondii: comparisons with pLDH from Plasmodium falciparum. Mol Biochem Parasitol. 2001;118:23–32. https://​doi.​org/​10.​1016/​S0166-6851(01)00360-7Targeting Lactate dehydrogenases of apicomplexan parasites.CrossRefPubMed
132.
•• El Bissati K, Zhou Y, Paulillo SM, Raman SK, Karch CP, Reed S, Estes A, Estes A, Lykins J, Burkhard P, & McLeod R. Engineering and characterization of a novel Self Assembling Protein for Toxoplasma peptide vaccine in HLA-A*11:01, HLA-A*02:01 and HLA-B*07:02 transgenic mice. Scientific Reports (Nature) September 2020. Potent imunosense protein self-assembling nanoaccine adjuvanted with GLA-SE protects HLA transgenic mice demonstrating effect of peptides where genetic restriction demonstrates protection is operative for three HLA Class I supermotifs.
133.
Del Valle Mojica, C. McLeod, R. et al. Late diagnosis of congenital toxoplasmosis with macrocephaly in two dizygotic twins after incidental detection of leukocoria: a case report. J Peds Infectious Diseases. 2021. Late symptomatic infection is treated medically in dizygotic twins.
134.
135.
Cong H, Mui EJ, Witola WH, Sidney J, Alexander J, Sette A, Maewal A, El Bissati K, Zhou Y, Suzuki Y, Lee D, Woods S, Sommerville C, Henriquez FL, Roberts CW, McLeod R. Toxoplasma gondii HLA-B*0702-restricted GRA7(20-28) peptide with adjuvants and a universal helper T cell epitope elicits CD8(+) T cells producing interferon-γ and reduces parasite burden in HLA-B*0702 mice. Hum Immunol. 2012;73:1–10.PubMedCrossRef
136.
•• Cong H, Mui EJ, Witola WH, Sidney J, Alexander J, Sette A, Maewal A, McLeod R. Human immunome, bioinformatic analyses using HLA supermotifs and the parasite genome, binding assays, studies of human T cell responses, and immunization of HLA-A*1101 transgenic mice including novel adjuvants provide a foundation for HLA-A03 restricted CD8+T cell epitope based, adjuvanted vaccine protective against Toxoplasma gondii. Immunome Res. 2010;6:12.PubMedPubMedCentralCrossRef
137.
•• Cong H, Mui EJ, Witola WH, Sidney J, Alexander J, Sette A, Maewal A, McLeod R. Towards an immunosense vaccine to prevent toxoplasmosis: protective Toxoplasma gondii epitopes restricted by HLAA*0201. Vaccine. 2011;29:754–62.PubMedCrossRef
138.
•• McLeod R, Lykins J, Noble AG, Rabiah P, Swisher C, Heydemann P, McLone D, Frim D, Withers S, Clouser F, Boyer K. Management of congenital toxoplasmosis. Curr Ped Rep. 2014;2(3):166–94 Review of management of congenital toxoplasmosis prior to 2014.CrossRef
139.
Van Wormer E, Fritz H, Shapiro K, Mazet JA, Conrad PA. Molecules to modeling: Toxoplasma gondii ooxyts at the human-animal-environment interface. Comp Immunol Microbiol Infect Dis. 2013;36(3):217–31 One health importance.
140.
•• McLeod R, Kieffer F, Sautter M, Hosten T, Pelloux H. Why prevent, diagnose and treat congenital toxoplasmosis? Mem Inst Oswaldo Cruz. 2009;104:320–44 Importance of diagnosis, prevention, and treatment.
141.
Olariu TR, Remington JS, McLeod R, Alam A, Montoya JG. Severe congenital toxoplasmosis in the United States: clinical and serologic findings in untreated infants. Pediatr Infect Dis J. 2011;30:1056–61 Reemphasizes severity of congenital toxoplasmosis in USA.
142.
•• Torgerson PR, Mastroiacovo P. The global burden of congenital toxoplasmosis: a systematic review. Bull World Health Organ. 2013;91(7):501–8. Emphasizes frequency and burden of congenital toxoplasmosis in the world and its considerable cost and suffering it causes. Early Panama study.
143.
Sousa OE, Saenz RE, Frenkel JK. Toxoplasmosis in Panama: a 10-year study. Am J Trop Med Hyg. 1988;38(2):315–22.PubMedCrossRef
144.
Pappas G, Roussos N, Falagas ME. Toxoplasmosis snapshots: global status of Toxoplasma gondii seroprevalence and implications for pregnancy and congenital toxoplasmosis. Int J Parasitol. 2009;39:1385–94 Prevalence data globally in earlier decades.
145.
Rosso F, Les JT, Agudelo A, Villalobos C, Chaves JA, Tunubala GA, Messa A, Remington JS, Montoya JG. Prevalence of infection with Toxoplasma gondii among pregnant women in Cali, Colombia, South America. Am J Trop Med Hyg. 2008;78(3):504–8 Prevalence in Cali Colombia 2008.
146.
Castro AT, Congora A, Gonzalez ME. Toxoplasma gondii antibody seroprevalence in pregnant women from Villavicencio, Colombia. Orinoquia. 2008;12:91–100 Prevalence Colombia.
147.
Barrera AM, Castiblanco P, Gomez-Marin JE, Lopez MC, Ruiz A, Moncada L, Reyes P, Corredor A. Toxoplasmosis adquirida durante el embarazo, en el Instituto Materno Infantil en Bogotá. Rev Sal Púb. 2002;4(3):286–93 Prevalence Colombia.
148.
Zapata M, Reyes L, Holst I. Disminución en la prevalencia de anticuerpos contra Toxoplasma gondii en adultos del valle central de Costa Rica. Parasitol Latinoam. 2005;60:32–7. Prevalence.
149.
150.
•• Arranz-Solís D, Carvalheiro CG, Zhang ER, Grigg ME, Saeij JPJ. Toxoplasma GRA peptide-specific serologic fingerprints discriminate among major strains causing toxoplasmosis. Front Cell Infect Microbiol. 2021;11:621738 Advanced serotyping.
151.
Pomares C, Devillard S, Holmes TH, Olariu TR, Press CJ, Ramirez R, Talucod J, Estran R, Su C, Dubey JP, Ajzenberg D. Genetic characterization of Toxoplasma gondii DNA samples isolated from humans living in North America: an unexpected high prevalence of atypical genotypes. J Infect Dis. 2018;218(11):1783–91 Genotype snapshot varied in US.
152.
•• Vasconcelos-Santos DV, Azevedo DO, Campos WR, Oréfice F, Queiroz-Andrade GM, Carellos ÉV, Romanelli RM, Januário JN, Resende LM, Martins-Filho OA, Carneiro AC. Congenital toxoplasmosis in southeastern Brazil: results of early ophthalmologic examination of a large cohort of neonates. Ophthalmology. 2009;116(11):2199–205 High prevalence of congenital toxoplasmosis and retinal disease in Brazil. Epidemics occur associated with water.
153.
154.
Endres MM, Scheeren MFDC, Fiori HH. Ocular Outcome of Brazilian Patients With Congenital Toxoplasmosis. Pediatr Infect Dis J. 2021;40(1):e21–7. https://​doi.​org/​10.​1097/​INF.​0000000000002931​Part of a series of papers by Lago et al, Lago and Dubey demonstrating severity of congenital Toxoplasmosis in Brazil, manifestations, and efficacy of treatment.
Metadata
Title
Building Programs to Eradicate Toxoplasmosis Part I: Introduction and Overview
Authors
Mariangela Soberón Felín
Kanix Wang
Aliya Moreira
Andrew Grose
Karen Leahy
Ying Zhou
Fatima Alibana Clouser
Maryam Siddiqui
Nicole Leong
Perpetua Goodall
Morgan Michalowski
Mahmoud Ismail
Monica Christmas
Stephen Schrantz
Zuleima Caballero
Ximena Norero
Dora Estripeaut
David Ellis
Catalina Raggi
Catherine Castro
Davina Moossazadeh
Margarita Ramirez
Abhinav Pandey
Kevin Ashi
Samantha Dovgin
Ashtyn Dixon
Xuan Li
Ian Begeman
Sharon Heichman
Joseph Lykins
Delba Villalobos-Cerrud
Lorena Fabrega
José Luis Sanchez Montalvo
Connie Mendivil
Mario R. Quijada
Silvia Fernández-Pirla
Valli de La Guardia
Digna Wong
Mayrene Ladrón de Guevara
Carlos Flores
Jovanna Borace
Anabel García
Natividad Caballero
Claudia Rengifo-Herrera
Maria Theresa Moreno de Saez
Michael Politis
Kristen Wroblewski
Theodore Karrison
Stephanie Ross
Mimansa Dogra
Vishan Dhamsania
Nicholas Graves
Marci Kirchberg
Kopal Mathur
Ashley Aue
Carlos M. Restrepo
Alejandro Llanes
German Guzman
Arturo Rebellon
Kenneth Boyer
Peter Heydemann
A. Gwendolyn Noble
Charles Swisher
Peter Rabiah
Shawn Withers
Teri Hull
Chunlei Su
Michael Blair
Paul Latkany
Ernest Mui
Daniel Vitor Vasconcelos-Santos
Alcibiades Villareal
Ambar Perez
Carlos Andrés Naranjo Galvis
Mónica Vargas Montes
Nestor Ivan Cardona Perez
Morgan Ramirez
Cy Chittenden
Edward Wang
Laura Lorena Garcia-López
Juliana Muñoz-Ortiz
Nicolás Rivera-Valdivia
María Cristina Bohorquez-Granados
Gabriela Castaño de-la-Torre
Guillermo Padrieu
Juan David Valencia Hernandez
Daniel Celis-Giraldo
Juan Alejandro Acosta Dávila
Elizabeth Torres
Manuela Mejia Oquendo
José Y. Arteaga-Rivera
Dan L. Nicolae
Andrey Rzhetsky
Nancy Roizen
Eileen Stillwaggon
Larry Sawers
Francois Peyron
Martine Wallon
Emanuelle Chapey
Pauline Levigne
Carmen Charter
Migdalia De Frias
Jose Montoya
Cindy Press
Raymund Ramirez
Despina Contopoulos-Ioannidis
Yvonne Maldonado
Oliver Liesenfeld
Carlos Gomez
Kelsey Wheeler
Ellen Holfels
David Frim
David McLone
Richard Penn
William Cohen
Samantha Zehar
James McAuley
Denis Limonne
Sandrine Houze
Sylvie Abraham
Raphael Piarroux
Vera Tesic
Kathleen Beavis
Ana Abeleda
Mari Sautter
Bouchra El Mansouri
Adlaoui El Bachir
Fatima Amarir
Kamal El Bissati
Alejandra de-la-Torre
Gabrielle Britton
Jorge Motta
Eduardo Ortega-Barria
Isabel Luz Romero
Paul Meier
Michael Grigg
Jorge Gómez-Marín
Jagannatha Rao Kosagisharaf
Xavier Sáez Llorens
Osvaldo Reyes
Rima McLeod
Publication date
01-09-2022
Publisher
Springer US
Published in
Current Pediatrics Reports / Issue 3/2022
Electronic ISSN: 2167-4841
DOI
https://doi.org/10.1007/s40124-022-00269-w

Other articles of this Issue 3/2022

Current Pediatrics Reports 3/2022 Go to the issue

International Health (EG Lago and N Gupta, Section Editors)

Building Programs to Eradicate Toxoplasmosis Part IV: Understanding and Development of Public Health Strategies and Advances “Take a Village”

International Health (EG Lago and N Gupta, Section Editors)

Building Programs to Eradicate Toxoplasmosis Part II: Education

International Health (EG Lago and N Gupta, Section Editors)

Building Programs to Eradicate Toxoplasmosis Part III: Epidemiology and Risk Factors

Adolescent Medicine (MA Goldstein, Section Editor)

Pediatric to Adult Transition for Adolescents and Young Adults with Kidney Transplant